局限性高危肾细胞癌的辅助治疗。

Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma.

机构信息

Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Division of Urologic Oncology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

出版信息

Urol Clin North Am. 2020 Aug;47(3):345-358. doi: 10.1016/j.ucl.2020.04.007.

DOI:10.1016/j.ucl.2020.04.007

PMID:32600536

Abstract

This article reviews the use of adjuvant therapies for prevention of recurrence following resection of clinically localized renal cell carcinoma (RCC). Clinical trials evaluating adjuvant therapy for RCC have focused primarily on the use of tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors, which had improved outcome in patients with metastatic disease. However, all but 1 trial found no difference in disease-free survival in the adjuvant setting and none improved overall survival.

摘要

本文回顾了辅助治疗在预防肾细胞癌（RCC）局部切除后复发中的应用。评估 RCC 辅助治疗的临床试验主要集中在使用酪氨酸激酶抑制剂和哺乳动物雷帕霉素靶蛋白抑制剂上，这些药物在转移性疾病患者中改善了结局。然而，除了 1 项试验外，所有试验在辅助治疗中均未发现无病生存率的差异，也没有改善总生存率。